Efficacy of buffered and enteric-coated acetylsalicylic acid on platelet aggregation in patients with stable coronary artery disease and type 2 diabetes (CASCADE): rationale and design of a single-center observational comparative study

Aim. Enteric-coated acetylsalicylic acid (ASA) is released more slowly and is absorbed in smaller quantities and over a longer period of time, which may lead to bioavailability and antiplatelet effect decrease compared to conventional ASA. Patients with diabetes are characterized by increased platelet reactivity and a reduced pharmacodynamic response to ASA compared to individuals without diabetes. It seems rational to test the hypothesis that the use of ASA absorbed in the stomach may be more effective in patients with type 2 diabetes mellitus (T2D) and stable coronary artery disease (CAD).

Material and methods. This single-center, non-interventional comparative study will randomly select 200 adult patients of both sexes with stable CAD and T2D who were routinely prescribed a gastro-soluble ASA (Cardiomagnyl 75 mg/day) or an enteric-soluble ASA (Aspirin® Cardio 100 mg/day or Thrombo ASS® 100 mg/day) before inclusion in the study. According to the routinely prescribed therapy, patients will be divided into 2 following groups: patients taking Cardiomagnyl 75 mg/day and patients taking Aspirin® Cardio 100 mg/day or Thrombo ASS® 100 mg/day. The primary endpoint is the incidence of high residual platelet reactivity (HRPR) while taking ASA (resistance to ASA) according to the VerifyNow Aspirin Test.

Conclusion. CASCADE is the first study to evaluate the HRPR using the VerifyNow Aspirin Test in patients with stable CAD and T2D.

1. Laferrière C, Moazzami C, Belley-Côté E, et al. Aspirin for the Primary Prevention of Vascular Ischemic Events: An Updated Systematic Review and Meta-analysis to Support Shared Decision-Making. CJC Open. 2023;5(12):881-90. doi:10.1016/j.cjco.2023.08.011.

2. Melchinger H, Jain K, Tyagi T, Hwa J. Role of Platelet Mitochondria: Life in a Nucleus-Free Zone. Front Cardiovasc Med. 2019;6:153. doi:10.3389/fcvm.2019.00153.

3. An H, Chen J, Li S, Chen A. Pantoprazole and Vonoprazan Performed Well in Preventing Peptic Ulcer Recurrence in Low-Dose Aspirin Users. Dig Dis Sci. 2024;69(3):670-82. doi:10.1007/s10620-023-08233-4.

4. Dammann HG, Burkhardt F, Wolf N. Enteric coating of aspirin significantly decreases gastroduodenal mucosal lesions. Aliment Pharmacol Ther. 1999;13(8):1109-14. doi:10.1046/j.1365-2036.1999.00588.x.

5. Lanza FL, Royer GL Jr, Nelson RS. Endoscopic evaluation of the effects of aspirin, buffered aspirin, and enteric-coated aspirin on gastric and duodenal mucosa. N Engl J Med. 1980;303(3):136-8. doi:10.1056/NEJM198007173030305.

6. Hawthorne AB, Mahida YR, Cole AT, Hawkey CJ. Aspirin-induced gastric mucosal damage: prevention by enteric-coating and relation to prostaglandin synthesis. Br J Clin Pharmacol. 1991;32(1):77-83. doi:10.1111/j.1365-2125.1991.tb05616.x.

7. Cole AT, Hudson N, Liew LC, et al. Protection of human gastric mucosa against aspirin-enteric coating or dose reduction? Aliment Pharmacol Ther. 1999;13(2):187-93. doi:10.1046/j.1365-2036.1999.00470.x.

8. Blondon H, Barbier JP, Mahé I, et al. Gastroduodenal tolerability of medium dose enteric-coated aspirin: a placebo controlled endoscopic study of a new enteric-coated formulation versus regular formulation in healthy volunteers. Fundam Clin Pharmacol. 2000;14(2):155-7. doi:10.1111/j.1472-8206.2000.tb00404.x.

9. Petroski D. Endoscopic comparison of three aspirin preparations and placebo. Clin Ther. 1993;15(2):314-20.

10. Hoftiezer JW, Silvoso GR, Burks M, Ivey KJ. Comparison of the effects of regular and enteric-coated aspirin on gastroduodenal mucosa of man. Lancet. 1980;2(8195 pt 1): 609-12. doi:10.1016/s0140-6736(80)90282-2.

11. García Rodríguez LA, Hernández-Díaz S, de Abajo FJ. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol. 2001;52(5):563-71. doi:10.1046/j.0306-5251.2001.01476.x.

12. van Oijen MG, Dieleman JP, Laheij RJ, et al. Peptic ulcerations are related to systemic rather than local effects of low-dose aspirin. Clin Gastroenterol Hepatol. 2008;6(3):309-13. doi:10.1016/j.cgh.2007.12.018.

13. Sidorov AV. Antithrombotic effect of different acetylsalicylic acid drug formulations: is there a difference? Russian Journal of Cardiology. 2021;26(10):4734. (In Russ.) doi:10.15829/1560-4071-2021-4734.

14. Clerici B, Cattaneo M. Pharmacological Efficacy and Gastrointestinal Safety of Different Aspirin Formulations for Cardiovascular Prevention: A Narrative Review. J Cardiovasc Dev Dis. 2023;10(4):137. doi:10.3390/jcdd10040137.

15. Kedir HM, Sisay EA, Abiye AA. Enteric-Coated Aspirin and the Risk of Gastrointestinal Side Effects: A Systematic Review. Int J Gen Med. 2021;14:4757-63. doi:10.2147/IJGM.S326929.

16. Rocca B, Fox KAA, Ajjan RA, et al. Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. Eur Heart J. 2018;39(19):1672-86. doi:10.1093/eurheartj/ehy066.

17. Gigante B, Tamargo J, Agewall S, et al. Update on antithrombotic therapy and body mass: a clinical consensus statement of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and the European Society of Cardiology Working Group on Thrombosis. Eur Heart J Cardiovasc Pharmacother. 2024;10(7):614-45. doi:10.1093/ehjcvp/pvae064.

18. Barbarash OL, Karpov YuA, Panov AV, et al. 2024 Clinical practice guidelines for Stable coronary artery disease. Russian Journal of Cardiology. 2024;29(9):6110. (In Russ.) doi:10.15829/1560-4071-2024-6110.

19. Murray FE, Hudson N, Atherton JC, et al. Comparison of effects of calcium carbasalate and aspirin on gastroduodenal mucosal damage in human volunteers. Gut. 1996;38(1):11-4. doi:10.1136/gut.38.1.11.

20. Barkagan ZS, Kotovshchikova EF. Comparative analysis of the main and side effects of different forms of acetylsalicylic acid. Clin. pharmacol. ter. 2004;13(3):40-3. (In Russ.)

21. Yakovenko EP, Krasnolobova LP, Yakovenko AV, et al. Effect of acetylsalicylic acid preparations on morphofunctional state of gastric mucosa in elderly cardiac patients. Serdce. 2013;12(3):145-50. (In Russ.)

22. Vertkin AL, Aristarkhova OYu, Adonina EV, et al. Safety and pharmacoeconomic effectiveness of different acetylsalicylic acid preparations in patients with CHD. RMJ. 2009;8:570-5. (In Russ.)

23. Takada M, Fujimoto M, Hosomi K. Difference in risk of gastrointestinal complications between users of enteric-coated and buffered low-dose aspirin. Int J Clin Pharmacol Ther. 2014;52(3):181-91.

24. Endo H, Sakai E, Higurashi T, et al. Differences in the severity of small bowel mucosal injury based on the type of aspirin as evaluated by capsule endoscopy. Dig Liver Dis. 2012;44:833-8.

25. Hirata Y, Kataoka H, Shimura T, et al. Incidence of gastrointestinal bleeding in patients with cardiovascular disease: buffered aspirin versus enteric-coated aspirin. Scand J Gastroenterol. 2011;46:803-9.

26. Ajjan RA, Kietsiriroje N, Badimon L, et al. Antithrombotic therapy in diabetes: which, when, and for how long? Eur Heart J. 2021;42(23):2235-59. doi:10.1093/eurheartj/ehab128.

27. Ferreiro JL, Angiolillo DJ. Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation. 2011;123(7):798-813. doi:10.1161/CIRCULATIONAHA.109.913376.

28. Gurbel PA, Bliden KP, Tantry US. Defining platelet response to acetylsalicylic acid: the relation between inhibition of serum thromboxane B2 and agonist-induced platelet aggregation. J Thromb Thrombolysis. 2021;51(2):260-4. doi:10.1007/s11239-020-02334-x.

29. Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med. 1984;311(19):1206-11. doi:10.1056/NEJM198411083111902.

30. Harrison P, Segal H, Blasbery K, et al. Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry. Stroke. 2005;36(5):1001-5. doi:10.1161/01.STR.0000162719.11058.bd.

31. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001;88(3):230-5. doi:10.1016/s0002-9149(01)01631-9.

32. Venketasubramanian N, Agustin SJ, Padilla JL, et al. Comparison of Different Laboratory Tests to Identify "Aspirin Resistance" and Risk of Vascular Events among Ischaemic Stroke Patients: A Double-Blind Study. J Cardiovasc Dev Dis. 2022;9(5):156. doi:10.3390/jcdd9050156.

33. Dash P, Singh VK, Gautam D, et al. Aspirin resistance and blood biomarkers in predicting ischemic stroke recurrence: An exploratory study. Brain Circ. 2022;8(1):31-7. doi:10.4103/bc.bc_75_21.

34. Lordkipanidzé M, Pharand C, Schampaert E, et al. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J. 2007;28(14):1702-8. doi:10.1093/eurheartj/ehm226.

35. Maree AO, Curtin RJ, Dooley M, et al. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol. 2005;46(7):1258-63. doi:10.1016/j.jacc.2005.06.058.

36. Khan H, Zamzam A, Gallant RC, et al. Aspirin nonsensitivity in patients with vascular disease: Assessment by light transmission aggregometry (aspirin nonsensitivity in vascular patients). Res Pract Thromb Haemost. 2021;5(8):e12618. doi:10.1002/rth2.12618.

37. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ. 2008;336(7637): 195-8. doi:10.1136/bmj.39430.529549.BE.

38. Filkova AA, Panteleev MA, Sveshnikova AN. Reversible platelet aggregation in the presence of calcium ions: mechanisms and potential value. Pediatric Hematology/ Oncology and Immunopathology. 2019;18(3):120-9. (In Russ.) doi:10.24287/1726-1708-2019-18-3-120-129.

39. Stark B, Johnson C, Roth G. Global prevalence of coronary artery: an update from the global burden of disease study. JACC. 2024;83(13_Supplement):2320.

40. Lawler PR, Bhatt DL, Godoy LC, et al. Targeting cardiovascular inflammation: next steps in clinical translation. Eur Heart J. 2021;42(1):113-31. doi:10.1093/eurheartj/ehaa099.

41. Kobalava ZhD, Pisaryuk AS, Filkova AA, et al. Platelet phenotypes and practical aspects of platelet function testing in cardiology. Rational Pharmacotherapy in Cardiology. 2023;19(6):614-28. (In Russ.) doi:10.20996/1819-6446-2023-2981.

42. Cofer LB, Barrett TJ, Berger JS. Aspirin for the Primary Prevention of Cardiovascular Disease: Time for a Platelet-Guided Approach. Arterioscler Thromb Vasc Biol. 2022; 42(10):1207-16. doi:10.1161/ATVBAHA.122.318020.

43. Haastrup PF, Grønlykke T, Jarbøl DE. Enteric coating can lead to reduced antiplatelet effect of low-dose acetylsalicylic acid. Basic Clin Pharmacol Toxicol. 2015;116(3):212-5. doi:10.1111/bcpt.12362.

44. Batterman RC. Comparison of buffered and unbuffered acetylsalicylic acid. N Engl J Med. 1958;258(5):213-9. doi:10.1056/NEJM195801302580503.

45. Feldman M, Cryer B. Aspirin absorption rates and platelet inhibition times with 325-mg buffered aspirin tablets (chewed or swallowed intact) and with buffered aspirin solution. Am J Cardiol. 1999;84(4):404-9. doi:10.1016/s0002-9149(99)00324-0.

46. Cox D, Maree AO, Dooley M, et al. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke. 2006;37(8):2153-8. doi:10.1161/01.STR.0000231683.43347.ec.

47. Peace A, McCall M, Tedesco T, et al. The role of weight and enteric coating on aspirin response in cardiovascular patients. J Thromb Haemost. 2010;8(10):2323-5. doi:10.1111/j.1538-7836.2010.03997.x.